OraSure Technologies Reaffirms 4th Quarter 2013 Financial Guidance

OraSure Technologies Reaffirms 4th Quarter 2013 Financial Guidance

BETHLEHEM, Pa., Nov. 25, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc.
(Nasdaq:OSUR) announced today that it is reaffirming its fourth quarter 2013
financial guidance, which the Company last updated in a press release it
issued on November 21, 2013.

This reaffirmation is being made after the Company learned today that a
customer of its molecular collection systems subsidiary, DNA Genotek, received
a warning letter from the U.S. Food and Drug Administration (FDA) requesting
that this customer immediately discontinue marketing its service in the U.S.
This customer represented less than 5 percent of OraSure's 2013 consolidated
net revenues through September 30, 2013.

The Company continues to believe its consolidated net revenues will range from
$27.5 to $28.0 million and that its consolidated net income will be
approximately $0.07 - $0.08 per share for the fourth quarter of 2013.

About OraSure Technologies

OraSure Technologies is a leader in the development, manufacture and
distribution of oral fluid diagnostic and collection devices and other
technologies designed to detect or diagnose critical medical conditions. Its
innovative products include rapid tests for the detection of antibodies to HIV
and HCV at the point of care and testing solutions for detecting various drugs
of abuse. In July 2012, the Company received approval from the U.S. Food and
Drug Administration for the Company's OraQuick® In-Home HIV Test for sale
directly to consumers in the over-the-counter (OTC) market - making it the
first and only rapid OTC HIV test approved in the U.S. In addition, the
Company is a leading provider of oral fluid sample collection, stabilization
and preparation products for molecular diagnostic applications. OraSure's
portfolio of products is sold globally to various clinical laboratories,
hospitals, clinics, community-based organizations and other public health
organizations, research and academic institutions, distributors, government
agencies, physicians' offices, and commercial and industrial entities. The
Company's products enable healthcare providers to deliver critical information
to patients, empowering them to make decisions to improve and protect their
health.

For more information on OraSure Technologies, please visit www.orasure.com.

Important Information

This press release contains certain forward-looking statements, including with
respect to expected revenues and earnings/loss per share. Forward-looking
statements are not guarantees of future performance or results. Known and
unknown factors that could cause actual performance or results to be
materially different from those expressed or implied in these statements
include, but are not limited to: ability to market and sell products, whether
through our internal, direct sales force or third parties; ability to
manufacture products in accordance with applicable specifications, performance
standards and quality requirements; ability to obtain, and timing and cost of
obtaining, necessary regulatory approvals for new products or new indications
or applications for existing products; ability to comply with applicable
regulatory requirements; changes in relationships, including disputes or
disagreements, with strategic partners or other parties and reliance on
strategic partners for the performance of critical activities under
collaborative arrangements; failure of distributors or other customers to meet
purchase forecasts or minimum purchase requirements for the Company's
products; impact of replacing distributors; inventory levels at distributors
and other customers; ability to integrate and realize the full benefits of the
Company's acquisition of DNA Genotek; ability of DNA Genotek to achieve its
financial and strategic objectives and continue to increase its revenues;
ability to identify, complete, integrate and realize the full benefits of
future acquisitions; impact of competitors, competing products and technology
changes; impact of negative economic conditions and high unemployment;
reduction or deferral of public funding available to customers; competition
from new or better technology or lower cost products; ability to develop,
commercialize and market new products, including the OraQuick® In-Home HIV
test; market acceptance of oral fluid testing or other products; changes in
market acceptance of products based on product performance or other factors;
ability to fund research and development and other products and operations;
ability to obtain and maintain new or existing product distribution channels;
reliance on sole supply sources for critical products and components;
availability of related products produced by third parties or products
required for use of our products; history of losses and ability to achieve
sustained profitability; ability to utilize net operating loss carry forwards
or other deferred tax assets; volatility of our stock price; uncertainty
relating to patent protection and potential patent infringement claims;
uncertainty and costs of litigation relating to patents and other intellectual
property; availability of licenses to patents or other technology; ability to
enter into international manufacturing agreements; obstacles to international
marketing and manufacturing of products; ability to sell products
internationally, including the impact of changes in international funding
sources and testing algorithms; adverse movements in foreign currency exchange
rates; loss or impairment of sources of capital;ability to retain qualified
personnel; exposure to product liability and other types of litigation;
changes in international, federal or state laws and regulations; customer
consolidations and inventory practices; equipment failures and ability to
obtain needed raw materials and components; the impact of terrorist attacks
and civil unrest; and general political, business and economic conditions.
These and other factors are discussed more fully in the Company'sSecurities
and Exchange Commission filings, including its registration statements, Annual
Report on Form 10-K for the year ended December 31, 2012, Quarterly Reports on
Form 10-Q, and other filings with the SEC. Although forward-looking statements
help to provide information about future prospects, readers should keep in
mind that forward-looking statements may not be reliable. The forward-looking
statements are made as of the date of this press release and OraSure
Technologies undertakes no duty to update these statements.

CONTACT: Investor Contact:
         Ron Spair
         OraSure Technologies
         610-882-1820
         investorinfo@orasure.com

company logo
 
Press spacebar to pause and continue. Press esc to stop.